Explore 3 Stock Ideas & Industry Insights Download Free Report

News

SAB Biotherapeutics Q3 2026: $63.7M Nine-Month Net Loss

SAB Biotherapeutics, Inc. (NASDAQ:SABS) filed its quarterly report for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing a net loss of $22.3 million for the third quarter and a cumulative net loss of $63.7 million for the first …

Anjali Anand | 05 November 2026

Cronos Group Q3 2026: Net Revenue Rises to $63.5M

Cronos Group Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the three and nine months ended September 30, 2026, reporting net revenue of $63,450 thousand for the third quarter.

Aditi Sarkar | 05 November 2026

Cronos Group Reports Q3 2026 Financial Results

Cronos Group Inc. filed a Form 8-K with the SEC on November 5, 2026, announcing the release of its financial results for the third quarter ended September 30, 2026.

Shwetambri Chauhan | 05 November 2026

Lucky Strike Q1 FY2027 Preliminary Results Filed Nov 5

Lucky Strike Entertainment Corporation filed an 8-K on November 5, 2026, announcing preliminary financial results for the first quarter of fiscal year 2027, which ended on September 27, 2026.

Vinay Lochav | 05 November 2026

Akebia Therapeutics Q3 2026 10-Q: 277.7M Shares Outstanding

Akebia Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.

Shwetambri Chauhan | 05 November 2026

Lucky Strike Q1 FY2027: Revenue Rises to $302.6M

Lucky Strike Entertainment Corporation filed its Form 10-Q for the quarterly period ended September 27, 2026, with the SEC on November 5, 2026, reporting total revenues of $302.6 million and a net loss of $25.7 million for the quarter.

Shwetambri Chauhan | 05 November 2026

Cabaletta Bio Files Q3 2026 10-Q With 215.7M Shares Out

Cabaletta Bio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing financial and operational information as a late-stage clinical biotechnology company.

Aditi Sarkar | 05 November 2026

Arrow Electronics Q3 2026: Sales Hit $10.7 Billion

Arrow Electronics, Inc. filed its Form 10-Q with the SEC on November 5, 2026, reporting financial results for the quarterly period ended October 3, 2026, under NYSE:ARW.

Manish Choudhary | 05 November 2026

Collegium Pharmaceutical Q3 2026: Total Assets Hit $2.10B

Collegium Pharmaceutical, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing condensed consolidated financial statements and management discussion for the third quarter.

Vinay Lochav | 05 November 2026

Intensity Therapeutics Q3 2026: Net Loss Widens to $3.54M

Intensity Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 5, 2026, reporting a net loss of $3.544 million for the third quarter.

Manish Choudhary | 05 November 2026
Support

Hi! How can we help you today?

Loading…